Vanta Bioscience Ltd
BSE:540729
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vanta Bioscience Ltd
Inventory
Vanta Bioscience Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vanta Bioscience Ltd
BSE:540729
|
Inventory
₹77.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Inventory
₹34.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Syngene International Ltd
NSE:SYNGENE
|
Inventory
₹1.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
27%
|
CAGR 10-Years
14%
|
|
|
O
|
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
|
Inventory
₹2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sai Life Sciences Ltd
NSE:SAILIFE
|
Inventory
₹1.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
Inventory
₹3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vanta Bioscience Ltd
Glance View
Vanta Bioscience Ltd. engages in the full service preclinical contract research organization. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2017-10-06. The firm is engaged in research and development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies, as well as diagnostics and cosmetics, including clinical research. The company provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. The company also provides expert services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's subsidiaries include Vanta Clinical Research Limited and Vayam Research Solutions Limited.
See Also
What is Vanta Bioscience Ltd's Inventory?
Inventory
77.3m
INR
Based on the financial report for Sep 30, 2025, Vanta Bioscience Ltd's Inventory amounts to 77.3m INR.
What is Vanta Bioscience Ltd's Inventory growth rate?
Inventory CAGR 5Y
-13%
Over the last year, the Inventory growth was -14%. The average annual Inventory growth rates for Vanta Bioscience Ltd have been 2% over the past three years , -13% over the past five years .
